Toyota|$17.90 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.06 (¥3,959)+1.93%▲ (in JPY terms)
SoftBank|$31.29 (¥4,944)+1.90%▲ (in JPY terms)
MUFG|$22.00 (¥3,475)+1.82%▲ (in JPY terms)
Keyence|$511.18 (¥80,760)+2.27%▲ (in JPY terms)
Nintendo|$53.67 (¥8,479)+3.05%▲ (in JPY terms)
NTT|$1.10 (¥175)+0.69%▲ (in JPY terms)
Takeda|$39.39 (¥6,223)+0.65%▲ (in JPY terms)
Tokyo Electron|$67.28 (¥10,630)+2.56%▲ (in JPY terms)
Recruit|$116.59 (¥18,420)+0.22%▲ (in JPY terms)
ITOCHU|$14.46 (¥2,284)+2.84%▲ (in JPY terms)
Honda|$11.38 (¥1,798)+1.21%▲ (in JPY terms)
Shin-Etsu|$37.84 (¥5,978)+0.25%▲ (in JPY terms)
Tokio Marine|$3.53 (¥558)+2.89%▲ (in JPY terms)
Fast Retailing|$478.39 (¥75,580)-1.07%▼ (in JPY terms)
Toyota|$17.90 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.06 (¥3,959)+1.93%▲ (in JPY terms)
SoftBank|$31.29 (¥4,944)+1.90%▲ (in JPY terms)
MUFG|$22.00 (¥3,475)+1.82%▲ (in JPY terms)
Keyence|$511.18 (¥80,760)+2.27%▲ (in JPY terms)
Nintendo|$53.67 (¥8,479)+3.05%▲ (in JPY terms)
NTT|$1.10 (¥175)+0.69%▲ (in JPY terms)
Takeda|$39.39 (¥6,223)+0.65%▲ (in JPY terms)
Tokyo Electron|$67.28 (¥10,630)+2.56%▲ (in JPY terms)
Recruit|$116.59 (¥18,420)+0.22%▲ (in JPY terms)
ITOCHU|$14.46 (¥2,284)+2.84%▲ (in JPY terms)
Honda|$11.38 (¥1,798)+1.21%▲ (in JPY terms)
Shin-Etsu|$37.84 (¥5,978)+0.25%▲ (in JPY terms)
Tokio Marine|$3.53 (¥558)+2.89%▲ (in JPY terms)
Fast Retailing|$478.39 (¥75,580)-1.07%▼ (in JPY terms)

JP3475350009

2026-09-28 DAIICHI SANKYO COMPANY,LIMITED “Regarding the voluntary withdrawal of the US application for approval of ifinatamab deruxtecan (I-DXd/DS-7300) for advanced small cell lung cancer (291.1KB) PDF file will be displayed in a new window.”

by

2026-09-28 DAIICHI SANKYO COMPANY,LIMITED “Regarding the voluntary withdrawal of the US application for … 続きを読む

2026-09-24 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approval of trastuzumab deruxtecan (T-DXd/DS-8201) for postoperative drug therapy for HER2-positive early breast cancer (256.5KB) will open in a new window as a PDF file.”

by

2026-09-24 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approv … 続きを読む

2026-09-16 DAIICHI SANKYO COMPANY,LIMITED “Notice of two partial amendments to the approval of the anti-cancer drugs "Enhertu®" and "Datroway®" for the first-line treatment of metastatic breast cancer in Japan (257.4KB) PDF file will be displayed in a new window.”

by

2026-09-16 DAIICHI SANKYO COMPANY,LIMITED “Notice of two partial amendments to the approval of the anti- … 続きを読む

2026-09-14 DAIICHI SANKYO COMPANY,LIMITED “The latest data from the Phase 3 clinical trial of trastuzumab deruxtecan (T-DXd/DS-8201) for first-line treatment of non-small cell lung cancer with HER2 gene mutations, presented at the World Conference on Lung Cancer (WCLC 2026), will be displayed in a new window as a PDF file (282.8KB).”

by

2026-09-14 DAIICHI SANKYO COMPANY,LIMITED “The latest data from the Phase 3 clinical trial of trastuzuma … 続きを読む

2026-09-01 DAIICHI SANKYO COMPANY,LIMITED “Notice of Partial Approval for the EU Regarding the First-Line Treatment of HER2-Positive Breast Cancer with Enhertu® (trastuzumab deruxtecan) and Pertuzumab (224.4KB) PDF file will open in a new window.”

by

2026-09-01 DAIICHI SANKYO COMPANY,LIMITED “Notice of Partial Approval for the EU Regarding the First-Lin … 続きを読む

Contact